Downregulation of PTTG1 expression inhibits the proliferation and invasiveness and promotes the apoptosis of human prostate cancer LNCaP-AI cells.
- Author:
Xi-Liang CAO
1
;
Yang-Yang WEI
2
;
Xiao-Ming SONG
2
;
Ke-Quan LU
2
;
Wen-Chao YU
2
;
Yong-Qiang CHEN
3
;
Yong-Liang LIU
2
;
Jiang-Ping GAO
4
Author Information
1. Department of Urology, Huaihai Hospital of Bengbu Medical College / the 97th Hospital of PLA, Xuzhou, Jiangsu 221004, China.
2. Department of Urology, Huaihai Hospital of Bengbu Medical College / the 97th Hospital of PLA, Xuzhou, Jiangsu 221004, China..
3. Center for Tumor Treatment, Huaihai Hospital of Bengbu Medical College / the 97th Hospital of PLA, Xuzhou, Jiangsu 221004, China.
4. Department of Urology, General Hospital of PLA, Beijing, 100086, China.
- Publication Type:Journal Article
- Keywords:
LNCaP cell;
androgen-dependence;
androgen-deprivation therapy;
pituitary tumor transforming gene 1;
prostate cancer
- MeSH:
Androgen Antagonists;
pharmacology;
Apoptosis;
Cell Line, Tumor;
Cell Proliferation;
Down-Regulation;
Humans;
Male;
Neoplasm Invasiveness;
Prostatic Neoplasms;
drug therapy;
metabolism;
pathology;
RNA, Small Interfering;
metabolism;
Securin;
genetics;
metabolism;
Time Factors;
Transfection
- From:
National Journal of Andrology
2017;23(7):589-597
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of down-regulation of PTTG1 expression on the proliferation, invasiveness and apoptosis of androgen-independent human prostate cancer LNCaP-AI cells and their sensitivity to androgen antagonists.
METHODS:Human prostate cancer LNCaP-AI cells were transfected with siRNA targeting the PTTG1 gene using the Lipofectamine 2000 transfection reagent. The proliferation, invasiveness and apoptosis of the cells were detected by MTT, Transwell assay and flow cytometry, respectively. The protein expressions of PTTG1, p-Akt, and p-ERK were determined by Western blot and the mRNA expression of PTTG1 measured by agarose gel electrophoresis.
RESULTS:The siRNA expression vector markedly down-regulated the expression of PTTG1, which effectively suppressed the proliferation of the LNCaP-AI cells, with the inhibition rates of (19.47 ± 2.12), (24.01 ± 2.13) and (48.02 ± 2.22)% at 24, 48 and 72 hours, respectively, after transfection, with statistically significant differences among the three groups (P <0.05). The number of the cells passing through the polycarbonate film was remarkably decreased at 24, 48 and 72 hours (74.67 ± 9.85, 56.44 ± 8.66 and 37.33 ± 6.14) as compared with the baseline (111.11 ± 13.47) (P <0.01), while the apoptosis rate of the cells was significantly increased at 24, 48 and 72 hours (18.32 ± 0.94), (19.94 ± 1.30) and (21.73 ± 1.88)% in comparison with the baseline (［2.17 ± 0.49］%)， (P <0.05). PTTG1 siRNA combined with androgen antagonist flumatide exhibited even more significant effects in inhibiting the proliferation and promoting the apoptosis of the LNCaP-AI cells than either used alone, and in a flumatide dose-dependent manner. The inhibition and apoptosis rates of the LNCaP-AI cells treated with 50 nmol/L flumatide were (27.13 ± 3.52) and (3.94 ± 0.48)%, and those treated with siRNA + 50 nmol/L flumatide were (67.51 ± 5.13) and (19.93 ± 1.72)%, respectively, both with statistically significant differences between the two groups (P <0.05). The inhibition and apoptosis rates of the cells treated with 100 nmol/L flumatide were (43.72 ± 3.90) and (5.33 ± 0.66)%, and those treated with siRNA + 100 nmol/L flumatide were (73.19 ± 4.78) and (23.43 ± 1.76)%, respectively, both with statistically significant differences between the two groups (P <0.05).
CONCLUSIONS:The siRNA expression vector can down-regulate the expression of PTTG1, which can inhibit the proliferation and invasiveness of LNCaP-AI cells, promote their apoptosis, and increase their sensibility to androgen antagonists. Suppressing the expression of PTTG1 may enhance the effect of androgen-deprivation therapy on advanced prostate cancer.
